The pandemic put a spotlight on the biotech and pharmaceutical business with their prices for shares reached new heights due to the.
The big pharmaceutical companies have performed well through 2022, even as other industries struggle in the context of the crisis in living costs and the rise in inflation.
Wide exposure to the healthcare sector allows investors to profit from the increasing demand in the long term for healthcare services.
Pharma has seen significant changes over the last few years.
Although the Covid vaccines made news but years of research are getting fruitful for major players such as AstraZeneca as well as GlaxoSmithKline.
However, with the threat of a recession on the horizon, are pharmaceutical companies capable of maintaining their growth? It could be the right moment to buy biotech companies that have seen their stock prices plummet?
Covid vaccine Covid vaccine has increased AstraZeneca’s global visibility significantly. in February, it announced the highest revenue quarter ever, comprising $1.8billion due to the Covid vaccine as well as the sales of the $39 billion acquisition of Alexion. The company also raised its dividend by the highest amount in the past decade.
AstraZeneca is currently the second-largest FTSE 100 company by market size after it doubled the price of its shares in just five years. It is also an extremely popular investment for income funds like Artemis and the Columbia Threadneedle Equity Income fund in the UK.
The big pharma companies represented by FTSE 100’s constituents AstraZeneca as well as GlaxoSmithKline have been performing well in the market’s overall slump this year. The shares of both companies are up 28 percent and 8 percent, for the year to date according to Garry White, Charles Stanley’s chief investment analyst.
Sales of the Covid-19 vaccine are slowly easing, but the loosening of restrictions on pandemics has boosted sales for other vaccines. Sales of cancer medications have been growing and the biggest players have plenty of pipelines for possible new products under development.’
GSK has also done very well. In the initial quarter, sales grew by 32 percent and operating profits grew by 65 per cent.
However, it faces an uphill climb ahead following selling its business for consumers Haleon that is been listed at the London Stock Exchange.
The demerger is likely to alter the structure of GSK in the process of becoming an independent pharma group. Its business in consumer healthcare was mostly predictable and stable in its earnings, and its shares already plummeted since Haleon’s debut.
Although Haleon’s trading on its opening day was on the lower range of expectations If investors are looking for an income that is more steady, it could be a good investment.
Fundamentally, this is a desirable industry and business to take exposure to, given its defensive nature at times when market volatility is causing disruption according to Chris Beckett, head of equity research at Quilter Cheviot.
The business has established strong brand names and market positions in the fields of oral health as well as digestion health, pain relief and vitamins, as well as respiratory health, and there’s no reason why these can’t be sustained.’
What is the best way to ensure that pharmaceuticals are recession-proof?
The general demand for stocks has been resilient, despite the recession since they’re considered to be safer and have a higher level of security.
Ailsa Craig, the joint lead investment manager for International Biotechnology Trust says: “In times of economic downturn, food and healthcare are typically a top priority for people, and the need for medical treatment doesn’t diminish. Indeed, the percentage of people over 65 years old aged who are likely to require medical attention is predicted to double by the coming years.
So, while coverage for insurance could be reduced and causing some price pressures, particularly for non-essential treatments, the overall market sales in the pharmaceutical sector, especially of medicines that treat critical illnesses, aren’t likely to be significantly affected by a decline of economic activity.’
Conglomerates of healthcare have been historically comprised of a variety of businesses that cover pharmaceuticals, consumer health and animal health, while some may even have medical device companies.
It is believed that a larger range of individuals will give you an even more secure portfolio. Health care is considered to be defensive… pharmaceuticals can appear defensive, but you have to buy more items because they lose exclusivity. There are more peaks and troughs says Andrew Duncan, senior equity analyst at Killick.
How do investors decide which ones are best investments to make?
An investor should search for a company that has a good reputation for R&D and research (R&D) as well as a strong pipeline, and a track record for providing that pipeline Duncan. Duncan. It is essential to have plenty of eggs in your basket.
“We consider the broad direction of the travel… and are looking at investing in businesses that provide to the R&D world. Tools and life sciences field… there’s need for services, but we’re not relying on the popularity of one particular item or test.’
Businesses that stand to benefit from this market include the US-listed Thermofisher that specializes in scientific research and recently bought an enterprise for clinical trials.
Is it the right moment to invest in biotech stocks that are volatile?
Biotech companies, situated at the crossroads of tech and pharma, were also the winners of the vaccine bounce.
After soaring in 2020, biotech stocks have slid as investors have shifted away from stocks that are growing. It is worth noting that the Nasdaq biotechnology index experienced an unstable three years, with its highest in 2021 before an extended retraction.
This overshooting and adjustment in performance is typical of biotech companies, however the overall trend has been positive, with an outperformance compared to those of UK FTSE 100 over the last three years Craig adds. Craig.
International Biotechnology Trust is unusual among investment trusts that focus on growth that pay a large dividend. The current yield of 5.01 percent.
The trust has a wide range of companies, most of with a drug approval currently on the market. They include Horizon Therapeutics, Incite and Neurocrine.
Although biotech is an interesting market for investors, it’s extremely risky, and investors who purchase individual stocks are susceptible to extreme risk.
White states: “The present issue for businesses operating on the forefront in biotech lies with the fact that as with researchers and developers in the more conventional technology sectors, they require substantial money upfront to compete with in their R&D.
The revenues they earn from their products, even though they could be significant they are unlikely to come through in the near future. It’s all about “jam tomorrow”.
“This type of business is dependent on borrowing, and higher borrowing costs now means lower profits in the long run.
The sum of the interest that they soon have to pay will have an immediate impact on the value of these businesses within models used by City analysts. When interest rates rise as do future forecasts of earnings and price expectations are reduced.’
Biotech’s hottest product Oxford Nanopore has certainly suffered since its debut on the market in the year 2000. It’s dropped 32 percent since its initial listing, and is down 56 per cent over the course of the year.
In March, the company reported that its the annual loss jumped over PS100million due to costs related with its IPO and share-based payment. The company also suffered at the close of an agreement in partnership with the Department of Health and Social Care that provided quick Covid tests.
White continues: “The future of healthcare is certainly positive, with promising developments in areas such as the use of mRNA-based vaccinations, gene therapy and monoclonal antibody monoclonal.
However, the general sentiment toward biotech is generally in a cyclical fashion and the pressure to structurally improve the less sexy section remains significant.
The rising rates of interest, inflation and geopolitical instability add to the negativity surrounding these investments due to the time frame they must earn a profit which means they are long-term and risky investments.
Negative influences that could impact the outlook of the sector’s outlook remain in place for a while. It is expected for Big Pharma, with its numerous product lines and diverse sources of revenue, will continue be the preferred choice of investors to invest for a long time. In the present, safety is paramount.’
Copyright – Classicalnet